Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
68 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Lennox-Gastaut Syndrome - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Lennox-Gastaut Syndrome - Pipeline Review, H2 2016, provides an overview of the Lennox-Gastaut Syndrome (Central Nervous System) pipeline landscape. Lennox-Gastaut syndrome is a severe form of epilepsy that typically becomes apparent during infancy or early childhood. The most common types of seizures associated with Lennox-Gastaut syndrome are tonic and atonic seizures. Causes of Lennox-Gastaut syndrome include cortical dysplasia, congenital infections, stroke, trauma, perinatal hypoxia, infections of the central nervous system such as encephalitis or meningitis and a rare, genetic disorder called tuberous sclerosis. Treatment includes antiepileptic drugs, dietary therapy and surgery. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Lennox-Gastaut Syndrome - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Lennox-Gastaut Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Lennox-Gastaut Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Lennox-Gastaut Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 2, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.Lennox-Gastaut Syndrome. Lennox-Gastaut Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Lennox-Gastaut Syndrome (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Lennox-Gastaut Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Lennox-Gastaut Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Lennox-Gastaut Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Lennox-Gastaut Syndrome (Central Nervous System) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Lennox-Gastaut Syndrome (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Lennox-Gastaut Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Lennox-Gastaut Syndrome Overview 6 Therapeutics Development 7 Pipeline Products for Lennox-Gastaut Syndrome - Overview 7 Pipeline Products for Lennox-Gastaut Syndrome - Comparative Analysis 8 Lennox-Gastaut Syndrome - Therapeutics under Development by Companies 9 Lennox-Gastaut Syndrome - Therapeutics under Investigation by Universities/Institutes 10 Lennox-Gastaut Syndrome - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Lennox-Gastaut Syndrome - Products under Development by Companies 14 Lennox-Gastaut Syndrome - Products under Investigation by Universities/Institutes 15 Lennox-Gastaut Syndrome - Companies Involved in Therapeutics Development 16 Eisai Co Ltd 16 GW Pharmaceuticals Plc 17 INSYS Therapeutics Inc 18 Zogenix Inc 19 Lennox-Gastaut Syndrome - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 26 Drug Profiles 28 cannabidiol - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 cannabidiol - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 fenfluramine hydrochloride - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 NRP-2945 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 perampanel - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 Small Molecules to Inhibit Voltage Gated Sodium Channels for Lennox Gastaut Syndrome - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 Lennox-Gastaut Syndrome - Product Development Milestones 51 Featured News & Press Releases 51 Nov 22, 2016: New Data on Zogenixs ZX008 for Lennox Gastaut Syndrome & Dravet Syndrome to be Presented at 70th Annual American Epilepsy Society Meeting 51 Oct 28, 2016: Eisai To Initiate Two Phase III Clinical Studies For Antiepileptic Drug Perampanel (Fycompa) in Pediatric Patients With Partial-Onset or Primary Generalized Tonic-Clonic Seizures And In Patients With Seizures Associated With Lennox-Gastaut Syndrome 52 Sep 26, 2016: GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for Epidiolex (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome 54 Jun 27, 2016: GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results for Epidiolex (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome 56 Feb 25, 2016: Edison Issues ADR Update on GW Pharmaceuticals 58 Dec 07, 2015: GW Pharmaceuticals Announces New Physician Reports of Epidiolex Treatment Effect in Children and Young Adults With Treatment-Resistant Epilepsy 58 Jun 11, 2015: GW Pharmaceuticals Initiates Second Phase 3 Pivotal Study of Epidiolex in Lennox-Gastaut Syndrome 61 May 11, 2015: GW Pharmaceuticals Initiates Phase 3 Pivotal Study of Epidiolex (CBD) in Lennox-Gastaut Syndrome 62 Apr 23, 2015: Insys Therapeutics Commences Dosing in Phase 1/2 Safety and Pharmacokinetic Study of Cannabidiol Oral Solution in Pediatric Epilepsy Patients 63 Jan 12, 2015: Insys Therapeutics To Initiate Phase III study For An Epileptic Drug 63 Jun 25, 2014: Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol as a Potential Treatment for Rare Form of Epilepsy, Lennox-Gastaut Syndrome 64 May 07, 2014: GW Pharmaceuticals Receives Investigational New Drug From FDA for Phase 2/3 Clinical Trial of Epidiolex in the Treatment of Dravet Syndrome 64 Feb 28, 2014: GW Pharmaceuticals Receives Orphan Drug Designation by FDA for Epidiolex in the Treatment of Lennox-Gastaut Syndrome 65 Sep 25, 2006: FDA Approves New Epilepsy Indication For Lamictal 66 Jan 15, 2004: New Expanded Indication For Lamictal Offers Additional Treatment Options For Adults With Partial Seizures 66 Appendix 67 Methodology 67 Coverage 67 Secondary Research 67 Primary Research 67 Expert Panel Validation 67 Contact Us 67 Disclaimer 68
List of Tables
Number of Products under Development for Lennox-Gastaut Syndrome, H2 2016 7 Number of Products under Development for Lennox-Gastaut Syndrome - Comparative Analysis, H2 2016 8 Number of Products under Development by Companies, H2 2016 9 Number of Products under Investigation by Universities/Institutes, H2 2016 10 Comparative Analysis by Late Stage Development, H2 2016 11 Comparative Analysis by Clinical Stage Development, H2 2016 12 Comparative Analysis by Early Stage Development, H2 2016 13 Products under Development by Companies, H2 2016 14 Products under Investigation by Universities/Institutes, H2 2016 15 Lennox-Gastaut Syndrome - Pipeline by Eisai Co Ltd, H2 2016 16 Lennox-Gastaut Syndrome - Pipeline by GW Pharmaceuticals Plc, H2 2016 17 Lennox-Gastaut Syndrome - Pipeline by INSYS Therapeutics Inc, H2 2016 18 Lennox-Gastaut Syndrome - Pipeline by Zogenix Inc, H2 2016 19 Assessment by Monotherapy Products, H2 2016 20 Number of Products by Stage and Target, H2 2016 22 Number of Products by Stage and Mechanism of Action, H2 2016 24 Number of Products by Stage and Route of Administration, H2 2016 25 Number of Products by Stage and Molecule Type, H2 2016 27
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
